BB Biotech AG reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was CHF 0.017 million compared to CHF 0.06 million a year ago. Net loss was CHF 13.48 million compared to CHF 233.07 million a year ago. Basic loss per share from continuing operations was CHF 0.24 compared to CHF 4.23 a year ago. Diluted loss per share from continuing operations was CHF 0.24 compared to CHF 4.23 a year ago.
For the six months, revenue was CHF 0.522 million compared to CHF 0.783 million a year ago. Net loss was CHF 267.33 million compared to CHF 532.93 million a year ago. Basic loss per share from continuing operations was CHF 4.87 compared to CHF 9.66 a year ago. Diluted loss per share from continuing operations was CHF 4.87 compared to CHF 9.66 a year ago.